Citations

Clear

6274 citation(s) found for "To, Andrew".

In Reply
Fletcher, Christopher D.�M. , Inwards, Carrie Y., Montag, Anthony, Qualman, Stephen J., Krausz, Thomas, Rubin, Brian P. , Peabody, Terrance D. , Rosenberg, Andrew E. , Weiss, Sharon Whelan

Mayo Clinic

Archives of Pathology & Laboratory Medicine | February 11, 2021 | Volume: 131 | Issue: 5 | Pages: 681-682

10.5858/2007-131-681-ir Get It

Best Practices in Diagnostic Immunohistochemistry: Pleomorphic Cutaneous Spindle Cell Tumors
Folpe, Andrew L. , Cooper, Kumarasen

Mayo Clinic

Archives of Pathology & Laboratory Medicine | February 11, 2021 | Volume: 131 | Issue: 10 | Pages: 1517-1524

10.5858/2007-131-1517-bpidip | PMID 17922587 Get It

Abstract Context.—Pleomorphic cutaneous spindle cell tumors can be difficult to distinguish solely on histologic grounds. The use of ancillary immunohistochemical studies can greatly assist in this differential diagnosis. Objective.—To review histologic and immunohistochemical aspects of cutaneous spindle cell tumors and discuss a basic panel of markers to assist in the differential diagnosis. Data Sources.—English-language literature published between 1981 and 2005. Conclusions.—A basic immunohistochemistry panel for high-molecular-weight cytokeratin, melanocytic markers (S100 protein, HMB-45, Melan-A), smooth muscle actin, desmin, and endothelial markers (CD31, CD34) is effective in diagnosing most cutaneous spindle cell tumors.
Protocol for the Examination of Specimens From Patients With Soft Tissue Tumors of Intermediate Malignant Potential, Malignant Soft Tissue Tumors, and Benign/Locally Aggressive and Malignant Bone Tumors
Fletcher, Christopher D.�M. , Inwards, Carrie Y., Montag, Anthony, Qualman, Stephen J., Krausz, Thomas, Rubin, Brian P. , Peabody, Terrance D. , Rosenberg, Andrew E. , Weiss, Sharon Whelan

Mayo Clinic

Archives of Pathology & Laboratory Medicine | February 11, 2021 | Volume: 130 | Issue: 11 | Pages: 1616-1629

10.5858/2006-130-1616-pfteos | PMID 17076523 Get It

Benefits of Peer Support for Intensive Care Unit Survivors: Sharing Experiences, Care Debriefing, and Altruism
McPeake, Joanne , Iwashyna, Theodore J. , Boehm, Leanne M. , Hibbert, Elizabeth , Bakhru, Rita N. , Bastin, Anthony J. , Butcher, Brad W. , Eaton, Tammy L. , Harris, Wendy, Hope, Aluko A. , Jackson, James C. , Johnson, Annie, Kloos, Janet A. , Korzick, Karen , Meyer, Joel , Montgomery-Yates, Ashley , Slack, Andrew, Wade, Dorothy , Still, Mary, Netzer, Giora, Hopkins, Ramona O., Sevin, Carla M. , Mikkelsen, Mark E. , Quasim, Tara , Haines, Kimberley

Mayo Clinic

American Journal of Critical Care | February 11, 2021 | Volume: 30 | Issue: 2 | Pages: 145-149

10.4037/ajcc2021702 | PMID 33566086 Get It

Background After critical illness, patients are often left with impairments in physical, social, emotional, and cognitive functioning. Peer support interventions have been implemented internationally to ameliorate these issues. Objective To explore what patients believed to be the key mechanisms of effectiveness of peer support programs implemented during critical care recovery. Methods In a secondary analysis of an international qualitative data set, 66 telephone interviews with patients were undertaken across 14 sites in Australia, the United Kingdom, and the United States to understand the effect of peer support during recovery from critical illness. Prevalent themes were documented with framework analysis. Results Most patients who had been involved in peer support programs reported benefit. Patients described 3 primary mechanisms: (1) sharing experiences, (2) care debriefing, and (3) altruism. Conclusion Peer support is a relatively simple intervention that could be implemented to support patients during recovery from critical illness. However, more research is required into how these programs can be implemented in a safe and sustainable way in clinical practice.
Temperature‐corrected proton density fat fraction estimation using chemical shift‐encoded MRI in phantoms
Navaratna, Ruvini , Zhao, Ruiyang , Colgan, Timothy J. , Hu, Peng , Bydder, Mark , Bashir, Mustafa R. , Middleton, Michael S. , Serai, Suraj D. , Chenevert, Thomas L. , Smith, Mark A. , Henderson, Walter C. , Hamilton, Gavin , Shu, Yunhong , Tkach, Jean A. , Brittain, Jean H. , Hu, Houchun Harry , Serai, Suraj D , Shu, Yunhong , Trout, Andrew T , Hernando, Diego , Reeder, Scott B. , Hamilton, Gavin , Yokoo, Takeshi , Malyarenko, Dariya I. , Sirlin, Claude B. , Trout, Andrew T.

Mayo Clinic

Magnetic Resonance in Medicine | February 11, 2021 | Volume: 86 | Issue: 1 | Pages: 69-81

10.1002/mrm.28669 | PMID 33565112 Get It

PurposeChemical shift‐encoded MRI (CSE‐MRI) is well‐established to quantify proton density fat fraction (PDFF) as a quantitative biomarker of hepatic steatosis. However, temperature is known to bias PDFF estimation in phantom studies. In this study, strategies were developed and evaluated to correct for the effects of temperature on PDFF estimation through simulations, temperature‐controlled experiments, and a multi‐center, multi‐vendor phantom study.Theory and MethodsA technical solution that assumes and automatically estimates a uniform, global temperature throughout the phantom is proposed. Computer simulations modeled the effect of temperature on PDFF estimation using magnitude‐, complex‐, and hybrid‐based CSE‐MRI methods. Phantom experiments were performed to assess the temperature correction on PDFF estimation at controlled phantom temperatures. To assess the temperature correction method on a larger scale, the proposed method was applied to data acquired as part of a nine‐site multi‐vendor phantom study and compared to temperature‐corrected PDFF estimation using an a priori guess for ambient room temperature.ResultsSimulations and temperature‐controlled experiments show that as temperature deviates further from the assumed temperature, PDFF bias increases. Using the proposed correction method and a reasonable a priori guess for ambient temperature, PDFF bias and variability were reduced using magnitude‐based CSE‐MRI, across MRI systems, field strengths, protocols, and varying phantom temperature. Complex and hybrid methods showed little PDFF bias and variability both before and after correction.ConclusionCorrection for temperature reduces temperature‐related PDFF bias and variability in phantoms across MRI vendors, sites, field strengths, and protocols for magnitude‐based CSE‐MRI, even without a priori information about the temperature.
NCCN Guidelines Insights: Prostate Cancer, Version 1.2021
Schaeffer, Edward M. , Srinivas, Sandy, Antonarakis, Emmanuel S. , Armstrong, Andrew J. , Bekelman, Justin E. , Cheng, Heather H. , D’Amico, Anthony V. , Desai, Neil , Dorff, Tanya B. , Eastham, James A., Farrington, Thomas A., Gao, Xin , Horwitz, Eric M. , Kuettel, Michael, McKay, Rana R. , McKenney, Jesse K. , Netto, George J. , Pow‐Sang, Julio M. , Reiter, Robert E. , Richey, Sylvia, Roach, Mack , Rosenfeld, Stan, Shabsigh, Ahmad , Spratt, Daniel E. , Teply, Benjamin A. , Shead, Dorothy A. , Freedman-Cass, Deborah A., Antonarakis, Emmanuel S. , Davis, Brian J. , Spratt, Daniel E , Cheng, Heather H , Antonarakis, Emmanuel S , Teply, Benjamin A , Armstrong, Andrew J , Antonarakis, Emmanuel S , Ippolito, Joseph E. , Lang, Joshua M. , Penson, David F. , Tward, Jonathan D.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | February 9, 2021 | Volume: 19 | Issue: 2 | Pages: 134-143

10.6004/jnccn.2021.0008 | PMID 33545689 Get It

The NCCN Guidelines for Prostate Cancer address staging and risk assessment after a prostate cancer diagnosis and include management options for localized, regional, and metastatic disease. Recommendations for disease monitoring and treatment of recurrent disease are also included. The NCCN Prostate Cancer Panel meets annually to reevaluate and update their recommendations based on new clinical data and input from within NCCN Member Institutions and from external entities. This article summarizes the panel’s discussions for the 2021 update of the guidelines with regard to systemic therapy for metastatic castration-resistant prostate cancer.
Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Armstrong, Deborah K. , Alvarez, Ronald D. , Barroilhet, Lisa , Chen, Lee-may, Cristea, Mihaela , Eisenhauer, Eric , Gray, Heidi J. , Hakam, Ardeshir, Jain, Angela, Karam, Amer , Konecny, Gottfried E. , Mahdi, Haider , McHale, Michael , Miller, David S. , O’Malley, David M. , Percac‐Lima, Sanja , Ratner, Elena , Remmenga, Steven W., Vargas, Roberto , Werner, Theresa L. , Zsíros, Emese , Burns, Jennifer L. , Engh, Anita M. , Miller, David S , O'Malley, David M , Bakkum‐Gamez, Jamie N. , Behbakht, Kian , Berchuck, Andrew , DeRosa, Maria, Gershenson, David M. , Grisham, Rachel Nicole , Leath, Charles A , Liu, Joyce F. , Martin, Lainie P. , Matei, Daniela , McLean, Karen

Mayo Clinic

Journal of the National Comprehensive Cancer Network | February 8, 2021 | Volume: 19 | Issue: 2 | Pages: 191-226

10.6004/jnccn.2021.0007 | PMID 33545690 Get It

Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States and is the country’s fifth most common cause of cancer mortality in women. A major challenge in treating ovarian cancer is that most patients have advanced disease at initial diagnosis. These NCCN Guidelines discuss cancers originating in the ovary, fallopian tube, or peritoneum, as these are all managed in a similar manner. Most of the recommendations are based on data from patients with the most common subtypes─high-grade serous and grade 2/3 endometrioid. The NCCN Guidelines also include recommendations specifically for patients with less common ovarian cancers, which in the guidelines include the following: carcinosarcoma, clear cell carcinoma, mucinous carcinoma, low-grade serous, grade 1 endometrioid, borderline epithelial, malignant sex cord-stromal, and malignant germ cell tumors. This manuscript focuses on certain aspects of primary treatment, including primary surgery, adjuvant therapy, and maintenance therapy options (including PARP inhibitors) after completion of first-line chemotherapy.
Common questions and misconceptions about creatine supplementation: what does the scientific evidence really show?
Candow, Darren G. , Kreider, Richard B. , Rawson, Eric S., VanDusseldorp, Trisha A. , Willoughby, Darryn S. , Ziegenfuss, Tim N. , Antonio, Jose , Kreider, Richard B , António, José , Forbes, Scott C. , Gualano, Bruno , Jagim, Andrew R. , Smith‐Ryan, Abbie E.

Mayo Clinic

Journal of the International Society of Sports Nutrition | February 8, 2021 | Volume: 18 | Issue: 1 | Pages: No page available

10.1186/s12970-021-00412-w | PMID 33557850 Get It

Is Reading Performance Impaired in Glaucoma Patients With Preserved Central Vision?
Ikeda, Mariana C, Bando, André Hiroshi, Hamada, Koiti Uchida, Nakamura, Vinícius Pereira Leite, Prata, Tiago S. , Paranhos, Augusto , Tatham, Andrew J. , Gracitelli, Carolina P B

Mayo Clinic

Journal of Glaucoma | February 8, 2021 | Volume: 30 | Issue: 4 | Pages: e153-e158

10.1097/ijg.0000000000001806 | PMID 33534509 Get It

Precis: Although this sample with glaucoma had preserved central vision, they presented worse reading performance compared with similarly aged controls. Objective: To determine whether patients with glaucoma with preserved central vision have impaired reading performance compared with healthy controls. Methods: A cross-sectional study of 35 patients with glaucoma and 32 similarly aged controls with visual acuity better than 0.4 logMAR in both eyes. Each participant had a detailed ophthalmological examination followed by a 5-chart reading performance test using a Portuguese version of the Minnesota Low Vision Reading Test (MNREAD). Correlation between reading performance (reading speed) and ocular parameters was investigated. Results: Participants had an average age of 63.0±12.6 years. In the glaucoma group, mean deviation in the better and worse eyes was −6.29±6.36 and −11.08±0.23 dB, respectively. There was no significant difference in age, sex, rage, education, visual acuity, or systemic comorbidities between groups. Participants with glaucoma had significantly slower reading speeds, with an average of 83.2±25.12 compared with 102.29±29.57 words per minute in controls (P=0.006). Reading speed was slower for all 5 charts. Odds of glaucoma increased by 1.29 (95% confidence interval, 1.07-1.56; P=0.009) for each 10 words per minute decrease in average reading speed, with this relationship maintained after accounting for age, schooling, and visual acuity. Conclusions: Patients with mild to moderate glaucoma had worse reading performance compared with similarly aged controls, despite both having preserved central vision.
Variation in the Treatment of Multiple Myeloma in the Real World
Chhun, Leena, Zheng, Cheng , Piboonvaranggoon, Jayne, Mallick, Elora, Wren, Jennifer, Nam, Grace, Barquilla, Ricardo Lopez, Dardac, Alexandra, Blau, Sibel , Senecal, Francis M. , Namburi, Swathi, Cowan, Andrew J. , Bensinger, William, Kumar, Shaji , Richardson, Paul G. , Blau, C. Anthony , Richter, Joshua , Richardson, Paul Gerard Guy , Anderson, Kenneth C.

Mayo Clinic

Blood | February 8, 2021 | Volume: 136 | Issue: Supplement 1 | Pages: 43-44

10.1182/blood-2020-138705 Get It

Background: Here we describe an online network of patients with cancer, clinicians and researchers, layered on top of a comprehensive real world database of treatments and outcomes, continuously updated in near real time, and initially focused on multiple myeloma. Methods: Patients with multiple myeloma register at www.all4cure.com and sign HIPAA release forms to provide access to all of their medical records from all of the institutions from which they have received care. From the medical records, a structured dataset of treatments and lab results is extracted by a myeloma-dedicated team for display on each patient's de-identified, personalized dashboard. A discussion panel allows more than 1200 participating patients, clinicians and researchers to post comments or questions regarding each patient's specific circumstances. For each patient, lines of therapy and responses are determined according to IMWG and published criteria (Blood [2015] 126: 921-922). Here we report initial results from the treatments and responses among patients with multiple myeloma and plasma cell leukemia. Results: A total of 493 patients includes 26 with monoclonal gammopathy of undetermined significance (MGUS), 51 with smoldering myeloma, 408 with multiple myeloma, and 8 with primary plasma cell leukemia. Among patients with multiple myeloma, 42 (10.3%) had antecedent MGUS and/or smoldering myeloma. The average age is 65.6 (+/- 9.7). 50.9% are male and 49.1% are female. 42 states in the U.S. and 8 other countries are represented. Two patients with multiple myeloma had not started treatment by the time of this report. The remaining 414 patients with multiple myeloma or plasma cell leukemia received 1 to 16 lines of therapy. Among the 414 patients that received at least one line of therapy, a remarkable 89 distinct first line therapies were administered. The most common first line therapies were lenalidomide, bortezomib, dexamethasone (n=92), cyclophosphamide, bortezomib, dexamethasone (n=50), lenalidomide, bortezomib, dexamethasone + autologous stem cell transplant + lenalidomide maintenance (n=41), lenalidomide and dexamethasone (n=29), and bortezomib and dexamethasone (n=22). 62 patients received a first line therapy that was not received by any other patient in our database. This variation was attributable to participation in clinical trials, variation in the availability of drugs over time and different geographic locations, and the very large number of distinct combinations associated with multi-agent regimens. Seventy six percent of patients with multiple myeloma or plasma cell leukemia received a second line of therapy, 52% received a third line of therapy, 34% received a fourth line of therapy, 23% received a fifth line of therapy, and 18% received a sixth line of therapy. We observed a trend toward a decline in favorable responses with successive lines of therapy (Table 1) consistent with previous reports, with a correlation coefficient between the line of therapy and overall response rate of -0.74. Among the 76 patients who received 6 or more lines of therapy (247 lines of therapy in total), only 7 achieved stringent complete responses (sCRs), of which 5 were associated with a CAR-T therapy. Table 1 also shows a trend toward more rapid changes in treatment associated with later lines of therapy. 57 of 493 patients (12%) are deceased. Conclusions: Our findings reveal remarkable variation in the treatment of myeloma and provide a potentially valuable resource of up to date and current clinical features, prognosis, treatments, side effects, and outcomes of patients with myeloma in the real world. Table 1. Summary of lines of therapy and outcomes across 414 patients with multiple myeloma and plasma cell leukemia. The percentages of patients achieving sCR, ≥ PR (overall response rate - ORR), and ≥MR (clinical benefit rate - CBR) are shown for each line of therapy. Also depicted is the interval mortality and the mean and median number of days between the beginning of a line therapy and the beginning of the next line of therapy. Table Disclosures Richter: Janssen: Consultancy, Speakers Bureau; Celgene: Consultancy, Speakers Bureau; Sanofi: Consultancy; X4 pharmaceuticals: Consultancy; Oncopeptides: Consultancy; Adaptive biotechnologies: Consultancy; Secura bio: Consultancy; Astra Zeneca: Consultancy; BMS: Consultancy; Karyopharm: Consultancy; Antengene: Consultancy. Chhun:All4Cure: Current Employment. Zheng:All4Cure: Current Employment. Piboonvaranggoon:All4Cure: Current Employment. Mallick:All4Cure: Current Employment. Wren:All4Cure: Current Employment. Nam:All4Cure: Current Employment. Lopez Barquilla:All4Cure: Current equity holder in private company. Blau:All4Cure: Current equity holder in private company. Cowan:Janssen: Consultancy, Research Funding; Abbvie: Research Funding; Cellectar: Consultancy; Sanofi: Consultancy; Bristol Myers Squibb: Research Funding. Bensinger:BMS: Consultancy, Honoraria, Research Funding, Speakers Bureau; Sanofi: Consultancy, Honoraria, Research Funding, Speakers Bureau; Janssen: Consultancy, Honoraria, Research Funding, Speakers Bureau; Amgen: Consultancy, Honoraria, Research Funding, Speakers Bureau; GSK: Consultancy, Honoraria, Research Funding, Speakers Bureau; Regeneron: Consultancy, Honoraria, Research Funding, Speakers Bureau. Kumar:Amgen: Consultancy, Other: Research funding for clinical trials to the institution, Consulting/Advisory Board participation with no personal payments, Research Funding; Genecentrix: Consultancy; Celgene/BMS: Other: Research funding for clinical trials to the institution, Consulting/Advisory Board participation with no personal payments; Novartis: Research Funding; Merck: Consultancy, Research Funding; Janssen Oncology: Other: Research funding for clinical trials to the institution, Consulting/Advisory Board participation with no personal payments; Carsgen: Other, Research Funding; Dr. Reddy's Laboratories: Honoraria; Adaptive Biotechnologies: Consultancy; Takeda: Other: Research funding for clinical trials to the institution, Consulting/Advisory Board participation with no personal payments; AbbVie: Other: Research funding for clinical trials to the institution, Consulting/Advisory Board participation with no personal payments; MedImmune: Research Funding; Tenebio: Other, Research Funding; BMS: Consultancy, Research Funding; Karyopharm: Consultancy; Cellectar: Other; Sanofi: Research Funding; Genentech/Roche: Other: Research funding for clinical trials to the institution, Consulting/Advisory Board participation with no personal payments; Oncopeptides: Consultancy, Other: Independent Review Committee; IRC member; Kite Pharma: Consultancy, Research Funding. Richardson:Celgene/BMS, Oncopeptides, Takeda, Karyopharm: Research Funding. Anderson:Oncopep and C4 Therapeutics.: Other: Scientific Founder of Oncopep and C4 Therapeutics.; Bristol Myers Squibb: Membership on an entity's Board of Directors or advisory committees; Gilead: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees; Sanofi-Aventis: Membership on an entity's Board of Directors or advisory committees; Celgene: Membership on an entity's Board of Directors or advisory committees; Millenium-Takeda: Membership on an entity's Board of Directors or advisory committees. Blau:All4Cure: Current Employment, Current equity holder in private company.